|
Bladder
Cancer Diagnosis and Surveillance
with a Simple Urine Test |
|
|
|
|
Over
75,000 new cases of bladder
cancer are diagnosed in Western
Europe every year. Early
detection enables allows
93% of patients to survive
for over 5 years. Survival
rates decrease to only 10%
at 5 years in late stage
disease. Tumours may recur
in over 50% of patients with
transitional cell carcinomas
and requires regular surveillance.
Bladderwatch™ BTA is
a rapid, costeffective immuno-chromatographic
test that gives immediate
results. It is easy to use
with no need for special
training, and is small enough
to be used in any location.
|
|
|
|
•
|
Five
drops of urine are placed
into the sample well on the
cassette and the result appears
within five minutes.
|
|
|
•
|
A
line appearing in both windows
(test & control) indicates
a positive result.
|
|
|
|
|
|
|
|
 |
|
Features |
|
|
|
•
|
Rapid
bladder cancer detection |
|
•
|
Positive
/ Negative result within
5 minutes |
|
•
|
Increases
early detection rates |
|
•
|
Reduces
the need for cystoscopy |
|
•
|
Single
step point-of-care
test |
|
•
|
5
drops of urine with
no pre-treatment required |
|
•
|
Used
for primary and recurrent
bladder cancer detection |
|
•
|
18
month room temperature
shelf-life at room
temperature |
|
|
|
|
|
|
|
|
|
Technical
Specification |
|
|
|
For
more technical information
on this product please
download the data sheet.
.: coming
soon |
|
| |
|
|
|
|
|
